Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to TafluprostTimolol Fixed-Combination Therapy

المؤلفون المشاركون

Kitamura, Kazuyoshi
Kashiwagi, Kenji
Chiba, Tatsuya
Mabuchi, Fumihiko
Ishijima, Kiyotaka
Omoto, Shu
Kashiwagi, Fumiko
Godo, Takashi
Kogure, Satoshi
Goto, Teruhiko
Shibuya, Takashi
Tanabe, Jhoji
Tsukahara, Shigeo
Tsuchiya, Tadaharu
Tsumura, Toyoaki
Tokunaga, Takaharu
Hosaka, Osamu
Saito, Tetsunori

المصدر

Journal of Ophthalmology

العدد

المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-9، 9ص.

الناشر

Hindawi Publishing Corporation

تاريخ النشر

2018-02-21

دولة النشر

مصر

عدد الصفحات

9

التخصصات الرئيسية

الطب البشري

الملخص EN

Purpose.

To assess the efficacy and safety of switching from prostaglandin analog (PGA) monotherapy to tafluprost/timolol fixed-combination (Taf/Tim) therapy.

Subjects and Methods.

Patients with primary open-angle glaucoma, normal-tension glaucoma, or ocular hypertension who had received PGA monotherapy for at least 3 months were enrolled.

Patients were examined at 1, 2, and 3 months after changing therapies.

Subsequently, the patients were returned to PGA monotherapy.

The examined parameters included intraocular pressure (IOP) and adverse events.

A questionnaire survey was conducted after the switch to Taf/Tim therapy.

Results.

Forty patients with a mean age of 66.5 ± 10.3 years were enrolled; 39 of these patients completed the study protocol.

Switching to Taf/Tim significantly reduced the IOP from 18.2 ± 2.6 mmHg at baseline to 14.8 ± 2.5 mmHg at 1 month, 15.2 ± 2.8 mmHg at 2 months, and 14.9 ± 2.5 mmHg at 3 months (P<0.001).

Switching back to the original PGA monotherapy returned the IOP values to baseline levels.

Taf/Tim reduced the pulse rate insignificantly.

No significant differences were observed in blood pressure, conjunctival hyperemia, or corneal adverse events.

A questionnaire showed that the introduction of Taf/Tim did not significantly influence symptoms.

Conclusions.

Compared with PGA monotherapy, Taf/Tim fixed-combination therapy significantly reduced IOP without severe adverse events.

نمط استشهاد جمعية علماء النفس الأمريكية (APA)

Kitamura, Kazuyoshi& Chiba, Tatsuya& Mabuchi, Fumihiko& Ishijima, Kiyotaka& Omoto, Shu& Kashiwagi, Fumiko…[et al.]. 2018. Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to TafluprostTimolol Fixed-Combination Therapy. Journal of Ophthalmology،Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1196991

نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)

Kitamura, Kazuyoshi…[et al.]. Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to TafluprostTimolol Fixed-Combination Therapy. Journal of Ophthalmology No. 2018 (2018), pp.1-9.
https://search.emarefa.net/detail/BIM-1196991

نمط استشهاد الجمعية الطبية الأمريكية (AMA)

Kitamura, Kazuyoshi& Chiba, Tatsuya& Mabuchi, Fumihiko& Ishijima, Kiyotaka& Omoto, Shu& Kashiwagi, Fumiko…[et al.]. Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to TafluprostTimolol Fixed-Combination Therapy. Journal of Ophthalmology. 2018. Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1196991

نوع البيانات

مقالات

لغة النص

الإنجليزية

الملاحظات

Includes bibliographical references

رقم السجل

BIM-1196991